We design a cell‐penetrating peptide that disrupts the USP25‐SHLD2 interaction, which in turn impairs NHEJ repair and ultimately sensitizes cancer cells to chemotherapy in the patient‐derived xenografts (PDX) model. This evidence concerns the gene USP25 and cancer.